• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.29% Nasdaq Down3.25%

    Endocyte, Inc. (ECYT)

    -NasdaqGS
    3.02 Down 0.16(5.03%) Feb 5, 4:00PM EST
    ProfileGet Profile for:
    Endocyte, Inc.
    3000 Kent Avenue
    Suite A1-100
    West Lafayette, IN 47906
    United States - Map
    Phone: 765-463-7175
    Fax: 765-463-9271
    Website: http://www.endocyte.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:81

    Business Summary 

    Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial in recurrent prostate cancer patients. The company is also developing EC1788, a folate receptor-targeted SMDC that is in preclinical development stage to treat cancer; EC1669, which is in preclinical development stage to treat inflammatory diseases; and EC0371 that is in preclinical development stage for the treatment of polycystic kidney disease. In addition, it develops Etarfolatide, a companion imaging agent for its SMDCs that target folate receptor; and EC0652, a diagnostic imaging agent targeting prostate-specific membrane antigen. The company has a collaboration agreement with Merck Sharp & Dohme Research GmbH for the development and commercialization of Vintafolide. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Endocyte, Inc.

    Corporate Governance 
    Endocyte, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 7. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 8; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. P. Ron Ellis , 54
    Co-Founder, Chief Exec. Officer, Pres and Director
    707.00K1.03M
    Dr. Philip S. Low Ph.D., 68
    Co-Founder, Chief Scientific Officer and Director
    209.00K0.00
    Mr. Michael A. Sherman , 50
    Chief Financial Officer and Chief Operating Officer
    431.00K56.00K
    Dr. Christopher P. Leamon Ph.D., 50
    VP of R&D
    375.00K0.00
    Dr. Scot L. Harper Ph.D., 59
    VP of Clinical Operations
    351.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders